Results from Alder Biopharmaceutical’s phase 3 study demonstrated reductions in migraine following quarterly infusions of both 100 mg and 300 mg eptinezumab versus placebo in patients with episodic migraines.
Peter Goadsby, M.B., B.S., Director of the NIHR- Wellcome Trust Kingâ€™s Clinical Research, London, Professor of Neurology, University of California at San Francisco, explained the benefits of the recent FDA approval of the gammaCore non-invasive vagal nerve stimulator on patients suffering from cluster headaches.
Andres Kanner, MD, Professor of Clinical Neurology, Chief of Epilepsy Division from the University of Miami Miller School of Medicine addressed that there were several medications in the pipeline being tested for different aspects of epilepsy treatment.
Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics also discussed their teamâ€™s programs in type 2 diabetes. One is an activator of an enzyme called glucocynase â€“ a master regulator for glucose in the body. According to Altstiel, when glucose is too high, it either shuns it off to energy production or stores it in the form of glycogen. Itâ€™s an insulin independent way of how the body controls glucose.